|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


* Laboratory of Immunology,
Laboratory of Allergology and Clinical Immunology, and
Second Division of Dermatology, Istituto Dermopatico dellImmacolata, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy
| Abstract |
|---|
|
|
|---|
20% of the total T cells isolated from the tissue. Skin-derived T cells suppressed nickel-specific responses of peripheral blood CD25- T cells. In addition, 60 ± 14% of peripheral blood CD25+ Treg expressed the chemokine receptor CCR7 and strongly inhibited naive T cell activation in response to nickel. Finally, CD25+ T cells isolated from peripheral blood of nickel-allergic patients showed a limited or absent capacity to suppress metal-specific CD4+ and CD8+ T cell responses. The results indicates that in healthy individuals CD25+ Treg can control the activation of both naive and effector nickel-specific T cells. | Introduction |
|---|
|
|
|---|
, TNF-
, and IL-17 (4, 5). In contrast, IL-10-producing CD4+ cells may have a role in limiting the immune response and thus the tissue damage (6, 7, 8). Although most people come into contact with ubiquitous chemicals with sensitizing potentials, only a few individuals develop ACD. This suggests that under physiologic conditions the skin immune system possesses regulatory mechanisms to avoid immunopathologic reactions to haptens. Indeed, in mouse models the existence of specific tolerogenic mechanisms that prevent immune responses to skin-applied haptens has been clearly documented. Hapten-specific tolerance occurs in animals fed the allergen before cutaneous sensitization. Oral tolerance can be adoptively transferred to naive animals with spleen or lymph node CD4+ T cells or with a mixture of CD4+ and CD8+ T cells and requires IL-10 (9, 10). Moreover, haptens painted onto UV light-irradiated skin expand IL-10-secreting CD4+ T cells, which express high levels of CTLA-4 and suppress hapten-specific immune responses in vivo (11, 12).
Recently, a subset of CD4+ T regulatory cells (Treg) constitutively expressing the
-chain of the IL-2R (CD25) has been identified in both mice and humans (13, 14, 15). The current view is that CD25+ Treg originate from the thymus as a distinct T cell lineage involved in the maintenance of tolerance to self Ags (16, 17). CD25+ Treg constitute 510% of peripheral blood CD4+ T cells, express high levels of CTLA-4, and are naturally anergic in vitro to mitogens (18, 19, 20). Upon TCR triggering, CD25+ Treg inhibit CD4+ and CD8+ T cell proliferation and IL-2 release in an Ag- and cytokine-independent, but cell-to-cell contact-dependent fashion (21, 22). CD25+ Treg may originate also in peripheral lymphoid organs and regulate immune responses to environmental Ags. Consistent with this hypothesis, CD25+ Treg are expanded following oral feeding with Ags (23, 24). Moreover, CD25+ Treg can regulate immune responses to microorganisms and transplantation Ags (23, 24, 25, 26, 27, 28, 29). Interestingly, a conspicuous number of circulating CD25+ T cells coexpresses the skin-homing receptor cutaneous lymphocyte associated Ag (CLA), thus indicating their possible engagement in skin immunity (30, 31).
Here we investigated the capacity of CD25+ T cells to control immune responses to nickel. Our results indicate that CD25+ T cells actively regulate nickel-specific T cell responses in healthy individuals and may have a critical role in maintaining a condition of "silent inflammation" to ubiquitous environmental substances penetrating the skin.
| Materials and Methods |
|---|
|
|
|---|
Blood samples were obtained from six healthy individuals (aged 2538 years, four women and two men) with no history of allergies to metals and negative patch test to 5% nickel sulfate and from six patients (aged 2836 years, four women and two men) with a documented allergy to metals and moderate to intense positive patch test to nickel. Skin biopsies were obtained at the site of nickel application from three nonallergic subjects and three nickel-allergic patients after informed consent was obtained. The study was approved by the institute ethical committee.
Cell purification
PBMCs were separated by density gradient centrifugation over Lymphoprep (Nycomed-Pharmacia, Oslo, Norway). After extensive washing, PBMCs were left to adhere for 2 h at 37°C in petri dishes (6 x 106 cells/ml, 6 ml/dish) suspended in RPMI 1640 complemented with 2 mM glutamine, 1 mM sodium pyruvate, 1% nonessential amino acids, 0.05 mM 2-ME, 100 U/ml penicillin, and 100 µg/ml streptomycin (all from Invitrogen Italia, San Giuliano Milanese, Italy; complete RPMI) with 5% autologous plasma added. The nonadherent fraction was collected for T cell purification, whereas adherent cells were incubated for 30 min in 0.2% EDTA, detached with a cell scraper, and used as APCs for most of the functional assays. CD8+ T cells (
95% pure) were positively selected by incubating nonadherent cells with immunomagnetic beads coated with anti-CD8 mAb, followed by DETACHaBEAD CD4/CD8 (Dynal, Oslo, Norway) according to the manufacturers protocol. CD4+ T cells (
97% pure) were obtained from the CD8+-depleted fraction after incubation with a cocktail of anti-CD8, -CD11b, -CD16, -CD19, -CD36, and -CD56 mAbs conjugated with magnetic beads (Untouched CD4+ T cell isolation kit; Miltenyi Biotec, Gladbach, Germany). CD4+CD25+ (
85% pure) and CD4+CD25- (
93% pure) T cells were separated by positive and negative selection from the CD4+ population using MACS CD25 microbeads (Miltenyi Biotec), respectively. In selected experiments CD4+CD25+ cells were further purified in CLA+ (
90% purity) and CLA- (
95% purity) fractions using a biotin-conjugated, anti-CLA mAb (HECA-452, rat IgM; BD PharMingen, San Diego, CA), followed by anti-biotin magnetic beads (Miltenyi Biotec). CD4+CD25-CD45RA+ (
95% pure) and CD4+CD25-CD45RO+ (
95% pure) T cells were isolated by negative immunomagnetic separation by incubating total CD4+CD25- cells with anti-CD45RO (UCHL1, IgG2a) or anti-CD45RA (HI100, IgG2b) mAbs (both from BD PharMingen) for 20 min at 4°C, followed by anti-mouse IgG conjugated to immunomagnetic beads (Dynal).
T cell isolation from skin biopsies
Four-millimeter punch skin biopsies were performed 36 h after application of 5% nickel sulfate in petrolatum on three nonallergic subjects and three nickel-allergic patients. Skin samples were minced with a scalpel and placed in culture in complete RPMI with 5% autologous plasma and 60 U/ml of IL-2. After 9 days T cells emigrated from tissue samples were collected and left for 2 days in 96-well microplates in complete RPMI without IL-2 before phenotypic characterization and functional assays.
Preparation of monocyte-derived dendritic cells
Adherent PBMCs were depleted of CD2+, CD19+, and CD56+ cells by negative selection with mAb-coated immunomagnetic beads (Dynal). The resulting monocyte population (
90% CD14+ cells) was cultured in complete RPMI supplemented with 10% FBS (HyClone, Logan, UT) in the presence of 100 ng/ml recombinant human GM-CSF (Mielogen; Schering-Plough, Milan, Italy) and 200 U/ml recombinant human IL-4 (R&D Systems, Minneapolis, MN) at 37°C with 5% CO2. Medium was replaced after 3 days, and cells were used as APCs in proliferation assays on days 67 of culture. This procedure produced a
95% pure CD1a+ CD14- dendritic cell preparation. To induce maturation, LPS from Escherichia coli 055:B5 (Sigma-Aldrich, Milan, Italy) was added at 50 µg/ml for the last 24 h of culture.
T cell proliferation assays
PBMCs alone (250,000 cells/well) or purified T cell subsets (160,000 cells/well) plus autologous gamma-irradiated adherent cells (150,000 cells/well) were cultured in flat-bottom, 96-well plates in the presence or the absence of 20 µg/ml of nickel sulfate (Sigma-Aldrich) in complete RPMI plus 5% autologous plasma. To check their suppressive function, conditioning cells (either CD4+CD25+, CD4+ CD25+CLA+, or CD4+CD25+CLA- T cells subsets, or CD4+CD25- T cells as a control) were added to the responder T cells. To investigate whether CD4+CD25+ Treg required physical contact with responder T cells, CD4+CD25- T cells (500,000 cells/well) with irradiated autologous APCs (400,000/well) and 20 µg/ml nickel were placed in the lower chamber of Transwell plates (0.4-µm pore size, 24-well format; BD Biosciences, Franklin Lakes, NJ), whereas the conditioning CD4+CD25+ T cells (250,000 cells/well) were seeded in the upper chamber in the presence of APCs and 20 µg/ml nickel. As a positive control, CD4+CD25- and CD4+CD25+ T cells were seeded together in the lower chamber. In some experiments 10 µg/ml of anti-TGF-
(clone 9016.2, mouse IgG1) or anti-IL-10 (clone 23758.11, mouse IgG2b) mAbs (R&D Systems) or control IgG were added to the cultures. After 5 days cell cultures were pulsed with 2 µCi/ml of [3H]thymidine (Amersham Pharmacia Biotech, Little Chalfont, U.K.) for 16 h and harvested onto fiber-coated 96-well plates. Radioactivity incorporation was measured in a beta counter. Results are given as the mean counts per minute ± SD of triplicate cultures.
ELISA for cytokine release
T cell supernatants were collected from cultures after 3 days, filtered, and tested for IL-4, IL-10, and IFN-
content the using DuoSet ELISA System (R&D Systems) following the manufacturers instructions.
Antibodies
For immunohistochemistry and FACS analysis, pure mAb anti-human CD4 (SK3, mIgG1), CD8 (SK1, mIgG1), CD25 (2A3, mIgG1), CTLA-4 (BNI3, mIgG2a), CCR7 (2H4, mIgM), and CLA; PE-conjugated anti-CD25 (M-A251, mIgG1); FITC-conjugated anti-CD4 (SK3, mIgG1), anti-CD69 (L78, mIgG1), and anti-HLA-DR (L243, mIgG2a); and mouse and rat isotype controls were obtained from BD PharMingen. Secondary FITC- or PE-conjugated goat anti-mouse IgG were purchased from Southern Biotechnology Associates (Birmingham, AL); secondary, biotin-conjugated, goat anti-rat IgM was purchased from BD PharMingen, and PE-conjugated streptavidin was obtained from DAKO (Carpinteria, CA).
Immunohistochemistry
A patch test to 5% nickel sulfate applied on the back of healthy individuals and nickel-allergic patients was punch-biopsied at 36 h and frozen at -80°C in OCT compound. Five-micron cryostat sections were fixed in 4% paraformaldehyde for 5 min and pretreated for 15 min with PBS containing 0.3% hydrogen peroxide to block the endogenous peroxidase activity, and with protein block serum-free solution (DAKO) to block the nonspecific binding of primary and secondary Abs. Slides were incubated for 1 h at room temperature in a humid atmosphere with 2.5 µg/ml of anti-CD4, 1.2 µg/ml of anti-CD8, 0.5 µg/ml of anti-CD25, or 50 µg/ml of anti-CLA mAbs, followed by biotinylated anti-mouse (DAKO) or biotinylated anti-rat (BD PharMingen) secondary Ab for 10 or 30 min, respectively. Streptavidin-peroxidase (DAKO) was added for 10 min to the samples, and 3-amino-9-ethyl-carbazole (Vector Laboratories, Burlingame, CA) was used as substrate. Every step was followed by extensive washing in PBS. Slides were counterstained with hematoxylin.
Flow cytometric analysis
Purified cell populations were washed with PBS added to 1% human serum and 0.01% NaN3 and were stained with FITC- or PE-conjugated mAbs or primary mAbs, followed by the appropriate secondary FITC- or PE-conjugated Ab. Staining with matched isotype control Ig was included. Cells were analyzed with a FACScan equipped with Cell Quest software (BD Biosciences).
Statistical analysis
Wilcoxons signed rank test was used to compare differences in T cell proliferation. A value of p
0.05 was considered significant.
| Results |
|---|
|
|
|---|
Nickel is a potential skin sensitizer that continuously stimulates the immune system, given its ubiquitous distribution and the easy permeation through the skin barrier. As a result, most individuals, independently from their allergic status, possess circulating nickel-specific memory T cells that are mostly restricted to the CD4+ compartment (8). Here we investigated the nickel responsiveness of a purified fraction of PBMCs isolated from six healthy, nonallergic individuals. All subjects showed a significant CD4+, but not CD8+, nickel-specific T cell response (Fig. 1), confirming previously published data (8). Interestingly, when CD4+ T lymphocytes were depleted of the CD25+ fraction, resulting in 95% pure CD4+CD25- T cells, a strong increase (mean ± SD, 240 ± 60%; range, 144316%; p < 0.001) in nickel-specific responses was observed in all individuals. In contrast, CD4+CD25+ T cells were unresponsive to nickel in five of the six donors examined and responded poorly to the metal in the individual NA5.
|
At an optimal nickel concentration (20 µg/ml), CD4+CD25+ T cells failed to respond to the metal presented by adherent cells. To rule out the possibility that the threshold of activation or the APC requirement of CD25+ Treg could differ from those of CD25- T cells, responsiveness to increasing concentrations of nickel was assayed using adherent monocytes or monocyte-derived dendritic cells as APCs. The results confirmed the incapacity of CD4+CD25+ T cells to respond in vitro to the metal in terms of both proliferation and cytokine release (Fig. 2). CD25+ T cells spontaneously released a small amount of IL-10, independently of the presence of nickel in the culture. However, 72-h culture with monocytes in the presence, but not in the absence, of nickel induced surface expression of CTLA-4 Ag on both CD25+ (mean ± SD percentage of CTLA-4+ cells in the absence and the presence of nickel, 0.66 ± 0.23 and 3.56 ± 1.03%, respectively) and CD25- (mean ± SD percentage of CTLA-4+ cells in the absence and the presence of nickel, 0.09 ± 0.12 and 1.82 ± 1.14%, respectively) T lymphocytes (Fig. 2B and Table I), indicating that they were both triggered by the metal through the TCR (32). This result is in line with previous findings indicating higher CTLA-4 expression on CD25+ compared with CD25- T cells (20).
|
|
To definitively assess the inhibitory function of CD25+ T cells in T cell responses to nickel, we cocultured blood-derived CD4+CD25- T cells with autologous CD25+ lymphocytes in the presence of APCs. At a CD25-/CD25+ ratio of 2/1, the proliferative response of CD25- cells was strongly reduced (mean ± SD, 74 ± 12%; range, 5485%; p < 0.001) by the presence of CD25+ T cells in all six healthy individuals investigated (Fig. 3). In contrast, the addition of an equal number of CD25- T lymphocytes did not change or even augment T cell proliferation. Titration of the number of CD25+ cells added to the cocultures demonstrated that the magnitude of the inhibition, in terms of cell proliferation and IFN-
release, depended on the CD25-/CD25+ ratio, with maximal inhibition at 1/1 (Fig. 4). Neither anti-IL-10 nor anti-TGF-
blocking Abs could revert the suppression induced by CD25+ T cells (Fig. 5A), in line with the observation that cell-to-cell contact, but not soluble factors, mediates the inhibitory activity of CD25+ T cells (22). Indeed, CD25+ T cells failed to suppress nickel-specific CD25- T cell responses in Transwell plate experiments (Fig. 5B).
|
|
|
CLA is a sialylated membrane glycoprotein expressed by 1520% of circulating T lymphocytes that allows preferential homing to the skin. To evaluate the capacity of CD4+CD25+ T cells to be engaged in cutaneous immune responses, the expression of CLA was analyzed on circulating CD25+ T cells isolated from healthy individuals. As shown in Fig. 6A, peripheral blood CD25+ T cells failed to coexpress the CD69 activation marker and variably expressed HLA-DR. A high percentage of CD25+ T cells (2030%) expressed CLA. Similar results were obtained when CD25+ T cells from nickel-allergic individuals were analyzed (not shown). The majority of T cells involved in immune responses to skin-applied haptens expressed CLA (33). Thus, we wondered whether CD4+CD25+CLA+ and CD4+CD25+CLA- T cells differed in their capacity to inhibit nickel-specific T cell responses. The results indicated that purified CD25+CLA+ T cells were indeed more potent than CD25+CLA- cells to suppress nickel-specific CD4+CD25- T cell proliferation (83 vs 51% inhibition, respectively; p < 0.002; Fig. 6B).
|
Application of 5% nickel sulfate under occlusion on the skin of nickel-allergic individuals induces a strong inflammatory reaction, which develops in 2472 h and mimics natural occurring ACD. In contrast, in nonallergic individuals, nickel application to the skin is not followed by a clinically evident inflammatory response. Since nickel-reactive T cells can be isolated from the peripheral blood of nonallergic individuals, we hypothesized that in healthy donors, CD25+ Treg may have a role in preventing nickel-specific T cell activation at the site of hapten penetration. Biopsies at the site of a negative patch test to nickel (Fig. 7E, inset) were taken from three nonallergic donors at a relatively early time point (36 h) and were processed for immunohistochemistry. Infiltration of CLA+ (Fig. 7G) and CD4+ (Fig. 7E) T cells and a lower number of CD8+ T cells (Fig. 7F) were detected along with the presence of a significant number of CD25+ cells (Fig. 7H). In contrast, normal skin (Fig. 7D) contained rare CLA+, CD4+, or CD8+ cells and no CD25+ cells. This finding demonstrates that despite the absence of clinically visible inflammation, T lymphocytes, including CD25+ cells, are recruited at the site of hapten application in healthy individuals.
|
The latter observation neither excluded that CD25+ T cells could represent recently activated CD25- lymphocytes nor indicated their regulatory function. Thus, to functionally assess T cells infiltrating a negative patch test to nickel, punch biopsies were taken 36 h after nickel application, mechanically fragmented, and cultured as described in Materials and Methods. After 9 days, T cells emigrated from the tissue samples were collected and starved (without IL-2) for 48 h before cytofluorometric analysis and functional assays. The number of T cells obtained from a 4-mm skin biopsy was low compared with that in nickel-positive skin reactions from nickel-allergic subjects (9 x 105 ± 2 x 105 cells vs 8 x 106 ± 1.5 x 106 cells, respectively; n = 3). In contrast to the cells infiltrating positive skin reactions, T cells emigrated from negative skin tests were unable to proliferate or release cytokines in response to the metal (Fig. 8, A and B). CD25+ cells accounted for
30% of the total number of T cells isolated from the biopsy on day 6 (not shown), which was reduced to 20% after a 2-day period of starvation (Fig. 8C). At a later time point (4 days), the percentage of CD25+ T cells did not change significantly (not shown). Importantly, T cells derived from a negative patch tests, but not from a positive patch test, strongly inhibited nickel-specific responses of autologous CD4+CD25- T cells isolated from peripheral blood (p < 0.001; Fig. 8D). These results demonstrate that T cells recruited at the site of nickel challenge in healthy donors contain a fraction of CD25+ Treg and block the activation of nickel-reactive T lymphocytes.
|
Although the suppressive activity of CD25+ Treg on nickel T cell responses prevailed in the CLA+ fraction, a significant regulatory function was also provided by CD25+CLA- T cells. These Treg are unlikely to be attracted to the skin following hapten exposure, but may prevent nickel-specific T cell priming in secondary lymphoid organs. Indeed, cytofluorometric analysis of PBMCs revealed that 60 ± 14% (n = 4) of CD4+CD25+ T cells expressed the chemokine receptor CCR7, the ligand for CCL21, which strongly influences lymphocyte positioning into secondary lymphoid organs (34) (Fig. 9A). To assess the capacity of CD25+ Treg to regulate nickel-specific T cell priming in vitro, CD4+CD25- T cells from nonallergic subjects were separated into naive CD45RO-RA+ and memory CD45RO+RA- T lymphocytes and assayed for their nickel responsiveness in the presence of CD25+ Treg. Both memory and naive T cells from peripheral blood of healthy allergic individuals responded to nickel, with a higher proliferation of CD45RO+RA- T cells and a lower response of naive CD45RO-RA+ T lymphocytes (Fig. 9B). CD4+CD25+ T cells inhibited to a comparable degree both T cell subsets (p < 0.002), indicating that CD25+ Treg could have a role not only in blocking hapten-specific T cell activation in peripheral tissues, but also in preventing the expansion of specific memory-effector T cells at any contact with the hapten.
|
Our findings strongly suggested an important contribution of CD4+CD25+ T cells in the modulation of cutaneous immunity to nickel. In line with this hypothesis, we asked whether CD4+CD25+ T cells from nickel-allergic patients and healthy individuals differed in the capacity to suppress nickel-specific responses. The percentage of CD4+CD25+ T cells obtained from the peripheral blood of nickel-allergic patients did not differ significantly from that of nonallergic donors (not shown). However, in contrast to CD25+ T cells obtained from peripheral blood of nonallergic individuals, CD25+ T cells from nickel-allergic donors strongly proliferated in response to the metal (Fig. 10). The regulatory function of CD4+CD25+ T cells from nickel-allergic patients was absent or much fainter compared with that of CD25+ Treg from nonallergic subjects. In particular, CD4+CD25- cells cocultured with CD25+ T cells at a 2/1 ratio showed 50 and 25% decreased responses to nickel in patients A4 and A6 (p < 0.05), respectively, and nonsignificant effects in the remaining patients (Fig. 11A). Finally, CD25+ T cells from all allergic patients failed to inhibit nickel-specific CD8+ T cell responses in coculture experiments (Fig. 11B). Interestingly, when CD25+ T cells from nickel-allergic and nonallergic individuals were compared in their capacity to suppress allogeneic T cell responses, no significant differences were observed, indicating that the overall CD25+ Treg activity in nickel-allergic individuals was not compromised (data not shown).
|
|
| Discussion |
|---|
|
|
|---|
3%) of CD25+ cells up-regulates membrane expression of CTLA-4, which is induced by TCR triggering (32), suggesting that a minority of CD25+ Treg could specifically recognize the metal. CTLA-4 is a negative regulator of T cell activation by competing with CD28 for binding to the B7 family members expressed on APCs. CTLA-4 expression is higher on CD25+ T cells compared with the CD25- counterpart, and it can be involved in the suppressive activity of Treg (20, 36, 37). CLA expression identifies a fraction of T cells with a propensity to recirculate in the skin. CLA is acquired by T cells after Ag encounter in skin-draining lymph nodes and is modulated by multiple factors, including the type of APC and the cytokine environment (38). Interestingly, CD25+CLA+ and CD25+CLA- T cells differed in their suppressive activity, with CD25+CLA+ Treg much more efficient in regulating nickel-specific T cell responses.
In humans, CD25+ T cell positioning in peripheral tissues during inflammation and tumor progression has been clearly demonstrated (39, 40). To validate the hypothesis of a direct role of CD25+ Treg in cutaneous hypersensitivity to nickel, we investigated the characteristics of T cells infiltrating the site of a patch test to nickel applied on the skin of nonallergic individuals. In contrast to nickel-allergic patients, nonallergic subjects do not develop cutaneous inflammation in response to nickel applied at a concentration of 5% in petrolatum under occlusion for 4872 h despite the presence of nickel-reactive CD4+ T cells in their peripheral blood. Although such apparent contradiction may be explained in different ways, our data demonstrate that nickel-challenged skin of nonallergic individuals showed a significant infiltrate of mononuclear cells, including CD4+, CD8+, CLA+, and some CD25+ cells. These CD25+ cells comprise
20% of T cells isolated from nickel-challenged skin, they are anergic upon nickel restimulation in vitro, and importantly, they strongly suppressed nickel-specific activation of blood-derived CD4+CD25- lymphocytes. In comparison, T cells isolated from nickel-allergic donors strongly proliferate and secrete IFN-
when stimulated with nickel in vitro. These results indicate that in both allergic and nonallergic individuals, hapten application is followed by a rapid recruitment of T cells. However, in the latter, Treg recruitment appears to prevent the activation of effector T cell populations and the development of the inflammatory reaction. In contrast to Treg isolated from nonallergic subjects, CD25+ T cells isolated from the peripheral blood of nickel-allergic individuals display a limited capacity to regulate nickel-specific CD4+CD25- T cell responses and completely fail to suppress CD8+ T cell responsiveness to the metal. Interestingly, the reduced regulatory activity of CD25+ T cells isolated from nickel-allergic individuals appears restricted to nickel-specific responses, since they suppress allo-specific T cell responses with the same efficiency as Treg isolated from healthy donors (data not shown). Thus, subjects that develop ACD in response to nickel may have a deficient function of their CD25+ Treg and a high number of metal-reactive CD8+ T cells. These two findings might be correlated, since it has been shown that CD25+ Treg are strongly involved in regulation of the memory/effector CD8+ T cell population (41). We also found that >50% of CD25+ Treg expressed the chemokine receptor, CCR7, which is involved in T cell homing to peripheral lymph nodes (34), and that CD25+ Treg strongly inhibit the in vitro activation of naive T cells to nickel. In this scenario, we hypothesize that CD25+ Treg modulate the outcome of immune responses toward skin-applied sensitizers with two mechanisms: a central mechanism mediated by CD25+CCR7+ Treg, which may limit the emergence of memory-effector hapten-specific T cells, CD8+ T lymphocytes in particular, and a peripheral mechanism mediated by CLA+CD25+ Treg, which can migrate in response to specific chemotactic stimuli in the skin and down-regulate activation of effector T cells at the site of hapten penetration, thus impeding the clinical manifestations of the allergic reaction.
Further investigations are required to establish the relative contributions of CD25+ Treg and other regulatory T cell subsets in the control of ACD reactions. In particular, we have previously characterized a subset of nickel-specific CD4+ T lymphocytes with regulatory activity that down-regulates the immune responses to the metal through the release of a high amount of IL-10. In contrast to CD25+ Treg, IL-10-releasing CD4+ T cells, also named Tr1 cells, do not require cell-to-cell contact for their suppressive function and act on APCs by blocking their IL-12 release and Ag-presenting functions (7). Tr1 recruitment at the site of nickel application is mostly promoted by the local release of CCL1, released by keratinocytes and infiltrating leukocytes late during ACD reaction (42). This finding suggests that Tr1 cells may be involved in the termination of the immune response to avoid excessive tissue damage.
In aggregate, our data strongly support the role of adaptive CD25+ Treg in the control of cutaneous immune responses to contact sensitizers and suggest that defective development of specific Treg may be critically involved in the expression of ACD in response to haptens. Insights into the origin and differentiation of adaptive CD25+ Treg could represent a critical step for therapeutic or preventive approaches of hapten-induced skin allergies.
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Andrea Cavani, Laboratory of Immunology, Istituto Dermopatico dellImmacolata, Istituto di Ricovero e Cura a Carattere Scientifico, Via Monti di Creta 104, I-00167 Rome, Italy. E-mail address: cavani{at}idi.it ![]()
3 Abbreviations used in this paper: ACD, allergic contact dermatitis; CLA, cutaneous lymphocyte-associated Ag; Treg, T regulatory cell. ![]()
Received for publication June 20, 2003. Accepted for publication September 29, 2003.
| References |
|---|
|
|
|---|
- and interleukin-4-induced activation of human keratinocytes. J. Invest. Dermatol. 115:81.[Medline]
-producing (Tc1) effector CD8+ T cells and interleukin (Il) 4/10-producing (Th2) negative regulatory CD4+ T cells. J. Exp. Med. 183:1001.
1 production and responsiveness. J. Exp. Med. 196:237.
-1,6-n-acetylglucosaminyltrasferase, an enzyme essential for biosynthesis of P-selectin ligands. J. Immunol. 167:4476.This article has been cited by other articles:
![]() |
H. Watanabe, S. Gehrke, E. Contassot, S. Roques, J. Tschopp, P. S. Friedmann, L. E. French, and O. Gaide Danger Signaling through the Inflammasome Acts as a Master Switch between Tolerance and Sensitization J. Immunol., May 1, 2008; 180(9): 5826 - 5832. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wu, K. Roelofs-Haarhuis, J. Zhang, M. Nowak, L. Layland, E. Jermann, and E. Gleichmann Dose dependence of oral tolerance to nickel Int. Immunol., August 13, 2007; (2007) dxm066v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Schneider, J. G. Meingassner, M. Lipp, H. D. Moore, and A. Rot CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells J. Exp. Med., April 16, 2007; 204(4): 735 - 745. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hirahara, L. Liu, R. A. Clark, K.-i. Yamanaka, R. C. Fuhlbrigge, and T. S. Kupper The Majority of Human Peripheral Blood CD4+CD25highFoxp3+ Regulatory T Cells Bear Functional Skin-Homing Receptors J. Immunol., October 1, 2006; 177(7): 4488 - 4494. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Tabbara, N. C. Peters, F. Afrin, S. Mendez, S. Bertholet, Y. Belkaid, and D. L. Sacks Conditions Influencing the Efficacy of Vaccination with Live Organisms against Leishmania major Infection Infect. Immun., August 1, 2005; 73(8): 4714 - 4722. [Abstract] [Full Text] [PDF] |
||||